LoewenKIDS - Infections & the Development of the Immune System

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine in what way infections, microbiome, and vaccinations during childhood interact in shaping the development of immunity and tolerance. The investigators collect and use data from a birth cohort focusing on infectious diseases during childhood and apply a life course perspective.

Clinical Trial Description

The goal of the study is to capture the complete history of exposure towards microbial challenges in the first six years of life and to study interactions between different components of microbial exposure as well as effects on the development of immunity. The investigators apply a diary in which parents document symptoms of respiratory and gastrointestinal infections of their child, and collect nasal swabs and stool samples obtained on first day of symptoms. In addition, the investigators collect nasal swabs and stool samples once per year during an asymptomatic period. The investigators intend to collect venous blood from children participating in the study at the age of six years. In a subsample (called intensive subcohort), the investigators collect asymptomatic probes three monthly during the first two years of life and obtain venous blood of the children at the age of one and two years. The study sample is 782 participants, with 285 participants in the intensive subcohort. Symptomatic samples will be analyzed by means of multiplex polymerase chain reaction (PCR). In addition, the investigators will assess microbial compositions based on next generation sequencing and apply multiplex panels to study parameters of unspecific humoral immune response. The study will allow to assess homologous and heterologous effects of infections and vaccinations measuring specific humoral immune response. In collaboration with immunologists, immune phenotypes will be studied and functional tests will be conducted. The investigators will use allergic dermatitis at the age of two as a primary proxy outcome and target asthma at the age of six years as a definitive clinical endpoint. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02654210
Study type	Observational
Source	Helmholtz Centre for Infection Research
Contact
Status	Active, not recruiting
Phase
Start date	March 2015
Completion date	February 2033

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02763345` - The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi	N/A
Completed	`NCT00550706` - Drug Utilization Prevalence in a Pediatric Care Medical Center	N/A
Completed	`NCT01033799` - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers	N/A
Completed	`NCT00761462` - BAY 0 9867 Cipro Pediatric Use Study (QUIP)	Phase 3
Completed	`NCT05088421` - A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers	Phase 1
Completed	`NCT00828971` - A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs	Phase 3
Completed	`NCT05468723` - Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1
Recruiting	`NCT02162966` - Safety and Efficacy Study of High Dose Colistin	Phase 4
Recruiting	`NCT00001281` - Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
Completed	`NCT02226263` - Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics	Phase 2
Terminated	`NCT00211471` - Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).	Phase 2
Active, not recruiting	`NCT04342702` - A Study on the Prospective Cohort Library of COVID-19 in Southeran
Completed	`NCT02134548` - Sensitivity Study of Diagnostic for Detection of Chagas Infection	N/A
Active, not recruiting	`NCT01611025` - Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time	N/A
Completed	`NCT01361997` - Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination	Phase 3
Completed	`NCT00638677` - Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier	Phase 4
Completed	`NCT02434848` - A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses	Phase 2/Phase 3
Completed	`NCT02544139` - Specificity Study of Diagnostic for Chagas Disease	N/A
Completed	`NCT00276198` - Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants	Phase 3
Completed	`NCT02111564` - A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

LoewenKIDS - Infections and the Development of the Immune System — LoewenKIDS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms